


Total Synthesis of Erythronolide A by Mg^{II}-Mediated Cycloadditions of Nitrile Oxides**

Dieter Muri, Nina Lohse-Fraefel, and Erick M. Carreira*

Since its discovery in 1952,^[1] erythromycin A has captured the imagination of research groups all over the world. The total syntheses of erythromycin A and its related derivatives (erythronolide A, erythromycin B, erythronolide B, (9*S*)-dihydroerythronolide A, 6-deoxyerythronolide B, 9,12-anhydroerythronolide A) have become benchmarks for the study of new methodologies in polyketide synthesis.^[2–4] We have recently reported a general approach for the synthesis of polyketide building blocks by means of Kanemasa's Mg^{II}-mediated cycloadditions of nitrile oxides to allylic alcohols.^[5] The nature of this approach allows the modular preparation of the entire spectrum of functionality and stereochemical permutations found in polyketide-derived structures. In this communication, we demonstrate the power and generality of this cycloaddition in the context of the total synthesis of erythronolide A (1). Erythronolide A was completed in 21 linear steps from the readily available oxime 2.^[5a] Of additional importance, we demonstrate the potential of the strategy to provide access to nonnatural analogues (ketolides) of this important agent.

The synthesis commences with the cycloaddition of oxime 2 to allylic alcohol 3; the former is available in three steps from (*S*)-methyl-3-hydroxyisobutyrate (Roche ester)^[6] and the latter in two steps by Noyori reduction of propargylic ketone and semihydrogenation over the Lindlar catalyst.^[7] Oxime 2 was treated with *t*BuOCl (−78 °C), which, after addition to a solution of *i*PrOH, EtMgBr, and 3, provided isoxazoline 4 in 86 % yield on a 35-mmol scale and with a diastereomeric ratio

of >95:5 as determined by ¹H NMR spectroscopy (Scheme 1). Oxidation of the secondary hydroxy group in 4 under conditions described by Ley et al.^[8] and treatment with Grignard reagent 6^[9] afforded tertiary alcohol 7 in 64 % yield



Scheme 1. Conditions: a) TPAP, NMO, CH₂Cl₂, RT, 1.5 h, 82%; b) 6, THF, −78 °C, 1 h, 64%, (d.r. > 98:2); c) TESOTf, 2,6-lutidine, CH₂Cl₂, 0 °C, 1 h, 93%; d) Raney Ni (W2), B(OH)₃, H₂, MeOH/H₂O, RT, 2 h, 89%; e) Zn(BH₄)₂, CH₂Cl₂, −30 °C, 2.5 h, 60% (d.r. > 95:5); f) PhCH(OMe)₂, CSA (10 mol%), toluene, 50 mbar, RT, 1.5 h, 87%; g) DDQ, pH 7 buffer, CH₂Cl₂, 0 °C, 2 h, 85%; h) TEMPO (15 mol%), NaOCl, KBr (10 mol%), pH 8.6 buffer, CH₂Cl₂, 0 °C, 10 min; i) H₂NOH·HCl, pyridine, EtOH, RT, 20 min, 85% (over 2 steps). CSA = camphorsulfonic acid, DDQ = 2,3-dichloro-5,6-dicyanobenzoquinone, NMO = *N*-methylmorpholine *N*-oxide, PMB = *para*-methoxybenzyl, TBS = *tert*-butyldimethylsilyl, TEMPO = 2,2,6,6-tetramethyl-1-piperidinyloxy, TESOTf = triethylsilyl trifluoromethanesulfonate, TPAP = tetrapropylammonium perruthenate.

(98:2 d.r., ¹H NMR). The tertiary hydroxy group was protected as triethylsilyl ether (93 % yield). Reductive cleavage of the N–O bond (Raney Ni, B(OH)₃, 93 % yield),^[10] *syn* reduction of the ensuing hydroxy ketone (Zn(BH₄)₂, 60 % yield),^[11] and protection of the isolated 1,3-diol provided 9 (87 % yield) as a single diastereomer (¹H NMR). Adduct 9 was converted to oxime 10 by a short three-step sequence of reactions in 72 % overall yield.


With oxime 10 in hand, we were ready for the second cycloaddition of a nitrile oxide. We were pleased to observe that this highly functionalized nitrile oxide smoothly underwent Mg^{II}-mediated 1,3-dipolar cycloaddition with allylic alcohol 3 under our standard reaction conditions (Scheme 2).^[6] Isoxazoline 11 was obtained in excellent yield (86 %) as a single diastereomer as determined by ¹H NMR spectroscopy. The nitrile oxide derived from 10 represents one of the most complex substrates used in dipolar cycloaddition reactions and attests to the versatility of the cycloaddition strategy for the synthesis of polyketides.

Oxidation of the secondary hydroxy group in 11 with TEMPO/NaOCl provided the corresponding ketone in 93 % yield, which was subjected to Wittig olefination^[12] (PrPPh₃Br and *t*BuLi) to give a trisubstituted olefin in 78 % yield and 33:1 *Z/E* ratio. Dihydroxylation of this olefin with (DHQD)₂PHAL/K₂OsO₄·2H₂O (4 mol%) furnished the 1,2-diol 12 in 81 % yield and 96:4 d.r.^[13,14] Selective deprotection of the primary *tert*-butyldimethylsilyl ether over the tertiary triethylsilyl ether could be accomplished with HF·pyridine/pyridine (1:3).^[15] Chemoselective two-step oxi-

[*] D. Muri, N. Lohse-Fraefel, Prof. Dr. E. M. Carreira
Laboratorium für Organische Chemie, ETH Hönggerberg
8093 Zürich (Switzerland)
Fax: (+41) 1-632-1328
E-mail: carreira@org.chem.ethz.ch

[**] This research was supported by the Swiss National Science Foundation and F. Hoffmann-LaRoche AG.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.




Scheme 2. Conditions: a) i) $t\text{BuOCl}$, CH_2Cl_2 , -78°C , 1.5 h, ii) $i\text{PrOH}$, EtMgBr , **3**, CH_2Cl_2 , $0^\circ\text{C} \rightarrow \text{RT}$, 86%, (d.r. > 99:1); b) TEMPO (15 mol %), NaOCl , KBr (10 mol %), pH 8.6 buffer, CH_2Cl_2 , 0°C , 1 h, 93%; c) PrPPPh_3Br , $t\text{BuLi}$, THF, $-78^\circ\text{C} \rightarrow \text{RT}$, 15 h, 78%, (Z:E 33:1); d) $(\text{DHQD})_2\text{PHAL}$ (20 mol %), $\text{K}_3[\text{Fe}(\text{CN})_6]$, MeSO_3NH_2 , K_2CO_3 , $\text{K}_2\text{OsO}_4 \cdot 2\text{H}_2\text{O}$, $t\text{BuOH}/\text{H}_2\text{O}$, 0°C , 2.5 h, 81% (d.r. 96:4); e) $\text{HF} \cdot \text{py} \cdot \text{py}$ (1:3), 0°C , 3 h, 80%; f) TEMPO (15 mol %), NaOCl , KBr (10 mol %), pH 8.6 buffer, CH_2Cl_2 , 0°C , 30 min; g) NaClO_2 , 2-methyl-2-butene, pH 3.8 buffer, $t\text{BuOH}$, 0°C , 30 min, 83% (over 2 steps). py = pyridine, $(\text{DHQD})_2\text{PHAL}$ = dihydroquinidine phthalazine ligand. R = TES.

dation (TEMPO/ NaOCl , NaClO_2 , 83% yield) completed the synthesis of erythronolide A seco acid **13**.


At the outset of this project, it was far from certain whether the cyclization could be successfully executed with the isoxazoline carboxylic acid **13**. The classic work of Woodward on the total synthesis of erythromycin A underscores the sensitivity of related macrolactonizations of carboxylic acids to the constellation of protecting groups.^[16] On the basis of modeling, we hypothesized that an isoxazoline bridging C9–C11 would lead to a favorable conformation of **13** and facilitate macrolactonization. Indeed, following a modified Yamaguchi protocol,^[17] the desired macrolactone was isolated in 78% yield without detection of any other cyclization by-products (Scheme 3). Deprotection of the triethylsilyl ether and subsequent N–O bond cleavage (Raney-Ni, AcOH) provided **15** in 93% yield, thus completing the formal total synthesis of erythronolide A. Treatment of **15** with $\text{Pd}(\text{OAc})_2$ for 6 h under an atmosphere of H_2 produced erythronolide A. Its ^1H and ^{13}C NMR spectra as well as melting point and optical rotation are identical with those of naturally derived erythronolide A.^[18]

An important aspect of this cycloaddition strategy would be the ability to access nonnatural polyketides. This approach



Scheme 3. Conditions: a) i) $2,4,6\text{-Cl}_3\text{C}_6\text{H}_2\text{COCl}$, NEt_3 , THF, 0°C , 30 min; ii) DMAP, toluene, 50°C , 4 h, 78%; b) $\text{HF} \cdot \text{NEt}_3$, NEt_3 , CH_3CN , RT, 64 h, > 99%; c) Raney-Ni (W2), AcOH, H_2 , EtOH, RT, 20 min, 93%; d) $\text{Pd}(\text{OAc})_2$, MeOH, H_2 , RT, 6 h, 40%. DMAP = 4-*N,N*-dimethylamino-pyridine.

would extend the methodology beyond an aldol-equivalent strategy to one that could provide unusual analogues not directly accessible either through genetic engineering or traditional synthetic methods. A number of erythromycin analogues investigated in the pharmaceutical industry are heterocyclic derivatives (bridging C9–C11, for example) prepared from the natural product.^[19] We thus became interested in the generation of nonnatural analogues such as **18** (Scheme 4). In a similar reaction sequence as described above, isoxazoline **4** could easily be converted to oxime **16** and subsequently to carboxylic acid **17**. Under modified Yamaguchi conditions, we obtained macrolactone **18** in 60% yield. Since the nitrile oxide and allylic alcohol partners can be varied readily, this strategy enables an approach to a plethora of



Scheme 4. Conditions: a) i) $2,4,6\text{-Cl}_3\text{C}_6\text{H}_2\text{COCl}$, NEt_3 , THF, 0°C , 30 min; ii) DMAP, toluene, 50°C , 4 h, 60%.

derivatives that may exhibit useful properties and allow the development of new antibiotics against multiresistant bacterial strains.

In summary, we have reported a stereoselective total synthesis of erythronolide A, whose focal points are two Mg^{II} -mediated cycloadditions of nitrile oxides, making this the shortest synthesis of erythronolide A to date: 21 linear steps, 4% overall yield. These accomplishments establish this methodology as a powerful tool for the synthesis of polyketide natural products. The isoxazoline serves as a robust protecting group for β -hydroxyketones that can be cleaved at a late stage of the synthesis within a densely functionalized structure. Moreover, the isoxazoline proved suitable for the delicate macrolactonization of erythronolide A seco acid **13**. Of broader significance, the strategy, beyond its use as an aldol equivalent process, opens up new possibilities for the preparation of nonnatural analogues.

Received: January 17, 2005

Published online: May 20, 2005

Keywords: asymmetric synthesis · cycloaddition · erythronolides · macrolactonization · nitrile oxides

- [1] J. M. McGuire, R. L. Bunch, R. C. Anderson, H. E. Boaz, E. H. Flynn, H. M. Powell, J. W. Smith, *Antibiot. Chemother.* **1952**, 2, 281.
- [2] The first total synthesis of an erythronolide analogue was reported in 1978: E. J. Corey, E. J. Trybulski, L. S. Melvin, Jr., K. C. Nicolaou, J. A. Secrist, R. Lett, J. R. Sheldrake, D. J. Brunell, M. F. Haslanger, S. Kim, S.-e. Yoo, *J. Am. Chem. Soc.* **1978**, 100, 4618; E. J. Corey, E. J. Trybulski, L. S. Melvin, Jr., K. C. Nicolaou, J. A. Secrist, R. Lett, J. R. Sheldrake, D. J. Brunell, M. F. Haslanger, S. Kim, S.-e. Yoo, *J. Am. Chem. Soc.* **1978**, 100, 4620.
- [3] For reviews on early synthetic work, see: a) I. Paterson, M. M. Mansuri, *Tetrahedron* **1985**, 41, 3569; b) J. Mulzer, *Angew. Chem.* **1991**, 103; *Angew. Chem. Int. Ed. Engl.* **1991**, 30, 1452.
- [4] For recent studies on the syntheses of erythromycins and erythronolides, see: a) R. Stürmer, K. Ritter, R. W. Hoffmann, *Angew. Chem.* **1993**, 105, 112; *Angew. Chem. Int. Ed. Engl.* **1993**, 32, 101; b) S. F. Martin, T. Hida, P. R. Kym, M. Loft, A. Hodgson, *J. Am. Chem. Soc.* **1997**, 119, 3193; c) D. A. Evans, A. S. Kim, R. Metternich, V. J. Novack, *J. Am. Chem. Soc.* **1998**, 120, 5921; d) P. J. Hergenrother, A. Hodgson, A. S. Judd, W.-C. Lee, S. F. Martin, *Angew. Chem.* **2003**, 115, 3400; *Angew. Chem. Int. Ed.* **2003**, 3278; e) Z.-H. Peng, K. A. Woerpel, *J. Am. Chem. Soc.* **2003**, 125, 6018.
- [5] a) J. W. Bode, N. Fraefel, D. Muri, E. M. Carreira, *Angew. Chem.* **2001**, 113, 2128; *Angew. Chem. Int. Ed.* **2001**, 40, 2082; b) for comprehensive reviews on cycloadditions of nitrile oxides, see: P. Caramella, P. Grünanger in *1,3-Dipolar Cycloaddition Chemistry, Vol. 1* (Ed.: A. Padwa), Wiley-Interscience, New York, **1984**, pp. 292–392; C. J. Easton, C. M. M. Hughes, G. P. Savage, G. W. Simpson, *Adv. Heterocycl. Chem.* **1994**, 60, 261; c) for applications of cycloadditions of nitrile oxides in the synthesis of heterocycles and natural products, see: “Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry Toward Heterocycles and Natural Products” by V. Jäger, P. A. Colinas in *The Chemistry of Heterocyclic Compounds, Vol. 59* (Eds.: A. Padwa, W. H. Pearson), Wiley, New York, **2002**, pp. 361–472.
- [6] Oxime **2** was prepared in three steps from (S)-methyl-3-hydroxyisobutyrate, which is available for less than 1 € per gram from Mitsubishi Rayon Co., Ltd. We would like to thank Mitsubishi Rayon Co. for a generous gift of (S)-methyl-3-hydroxyisobutyrate.
- [7] a) Several preparations of chiral olefin **3** have been reported; for our purposes it was prepared from enantiomerically pure 2-hydroxy-3-pentyne, itself prepared by the method of R. Noyori, *J. Am. Chem. Soc.* **1997**, 119, 8738; b) for another procedure, see: O. Hamed, P. M. Henry, *Organometallics* **1997**, 16, 4903.
- [8] W. P. Griffith, S. V. Ley, G. P. Whitecomb, A. D. White, *J. Chem. Soc. Chem. Commun.* **1987**, 1625.
- [9] Compound **6** was prepared from the corresponding bromide by lithium–halogen exchange with *t*BuLi and subsequent transmetalation with MgBr₂; the bromide is available in three steps from (S)-methyl-3-hydroxyisobutyrate: P. M. Smith, E. J. Thomas, *J. Chem. Soc. Perkin Trans. 1* **1998**, 3541.
- [10] a) D. P. Curran, *J. Am. Chem. Soc.* **1983**, 105, 5826; b) D. P. Curran, S. A. Scanga, C. J. Fenk, *J. Org. Chem.* **1984**, 49, 3474.
- [11] a) Y. Ito, M. Yamaguchi, *Tetrahedron Lett.* **1983**, 24, 5385; b) T. Nakata, Y. Tani, M. Hatozaki, T. Oishi, *Chem. Pharm. Bull.* **1984**, 32, 1411; c) D. A. Evans, M. D. Ennis, and T. Le, N. Mandel, G. Mandel, *J. Am. Chem. Soc.* **1984**, 106, 1154.
- [12] G. Wittig, U. Schöllkopf, *Chem. Ber.* **1954**, 87, 1318.
- [13] Substrate-directed dihydroxylation on a similar system proved troublesome; no diastereoselectivity was observed but the yield was excellent: S. D. Burke, F. J. Schoenen, M. S. Nair, *Tetrahedron Lett.* **1987**, 28, 4143.
- [14] For recent reviews on Sharpless asymmetric dihydroxylations, see: a) H. C. Kolb, M. S. VanNieuwenhze, K. B. Sharpless, *Chem. Rev.* **1994**, 94, 2483; b) R. A. Johnson, K. B. Sharpless in *Catalytic Asymmetric Synthesis* (Ed.: I. Ojima), VCH, New York, **2000**, pp. 357.
- [15] On a similar system, selective deprotection of the tertiary hydroxy group was observed under acidic conditions (dichloroacetic acid, MeOH, 0 °C).
- [16] Woodward’s early investigation revealed a 9-(S)-hydroxy group, protected as a cyclic acetal, ideal for a successful lactonization of the carboxylic acid: a) R. B. Woodward, E. Logusch, K. P. Nambiar, K. Sakan, D. E. Ward, B.-W. Au-Yeung, P. Balaram, L. J. Browne, P. J. Card, C. H. Chen, R. B. Chênevert, A. Fliri, K. Frobél, H.-J. Gais, D. G. Garratt, K. Hayakawa, W. Heggie, D. P. Hesson, D. Hoppe, I. Hoppe, J. A. Hyatt, D. Ikeda, P. A. Jacobi, K. S. Kim, Y. Kobuke, K. Kojima, K. Krowicki, V. J. Lee, T. Leutert, S. Malchenko, J. Martens, R. S. Matthews, B. S. Ong, J. B. Press, T. V. Rajan Babu, G. Rousseau, H. M. Sauter, M. Suzuki, K. Tatsuta, L. M. Tolbert, E. A. Truesdale, I. Uchida, Y. Ueda, T. Uyehara, A. T. Vasella, W. C. Vlodechick, P. A. Wade, R. M. Williams, H. N.-C. Wong, *J. Am. Chem. Soc.* **1981**, 103, 3210; b) R. B. Woodward, E. Logusch, K. P. Nambiar, K. Sakan, D. E. Ward, B.-W. Au-Yeung, P. Balaram, L. J. Browne, P. J. Card, C. H. Chen, R. B. Chênevert, A. Fliri, K. Frobél, H.-J. Gais, D. G. Garratt, K. Hayakawa, W. Heggie, D. P. Hesson, D. Hoppe, I. Hoppe, J. A. Hyatt, D. Ikeda, P. A. Jacobi, K. S. Kim, Y. Kobuke, K. Kojima, K. Krowicki, V. J. Lee, T. Leutert, S. Malchenko, J. Martens, R. S. Matthews, B. S. Ong, J. B. Press, T. V. Rajan Babu, G. Rousseau, H. M. Sauter, M. Suzuki, K. Tatsuta, L. M. Tolbert, E. A. Truesdale, I. Uchida, Y. Ueda, T. Uyehara, A. T. Vasella, W. C. Vlodechick, P. A. Wade, R. M. Williams, H. N.-C. Wong, *J. Am. Chem. Soc.* **1981**, 103, 3213; R. B. Woodward, E. Logusch, K. P. Nambiar, K. Sakan, D. E. Ward, B.-W. Au-Yeung, P. Balaram, L. J. Browne, P. J. Card, C. H. Chen, R. B. Chênevert, A. Fliri, K. Frobél, H.-J. Gais, D. G. Garratt, K. Hayakawa, W. Heggie, D. P. Hesson, D. Hoppe, I. Hoppe, J. A. Hyatt, D. Ikeda, P. A. Jacobi, K. S. Kim, Y. Kobuke, K. Kojima, K. Krowicki, V. J. Lee, T. Leutert, S. Malchenko, J. Martens, R. S. Matthews, B. S. Ong, J. B. Press, T. V. Rajan Babu, G. Rousseau, H. M. Sauter, M. Suzuki, K. Tatsuta, L. M. Tolbert, E. A. Truesdale, I. Uchida, Y. Ueda, T. Uyehara, A. T. Vasella, W. C. Vlodechick, P. A. Wade, R. M. Williams, H. N.-C. Wong, *J. Am. Chem. Soc.* **1981**, 103, 3215.
- [17] a) J. Inanaga, K. Hirata, H. Saeki, T. Katsuki, M. Yamaguchi, *Bull. Chem. Soc. Jpn.* **1979**, 52, 1989; studies in the context of erythronolide macrolactonization: Y. Sakurai, M. Hikota, K. Horita, O. Yonemitsu, *Chem. Pharm. Bull.* **1992**, 40, 2540.
- [18] a) Formation of erythromycin A oxime, see: A. M. Costa, J. Vilarasa, *Tetrahedron Lett.* **2000**, 41, 3371; b) Glycoside cleavage, see: R. A. LeMahieu, M. Carson, R. W. Kierstead, *J. Antibiot.* **1975**, 28, 704; c) Regeneration of the ketone, see: R. A. LeMahieu, M. Carson, R. W. Kierstead, L. M. Fern, *J. Med. Chem.* **1974**, 17, 953.
- [19] For recent modifications, see, for example: a) Y. Watanabe, T. Adachi, T. Asaka, M. Kashimura, S. Morimoto, *Heterocycles* **1990**, 31, 2121; b) R. L. Elliott, D. Pireh, G. Griesgraber, A. M. Nilius, P. J. Ewing, M. H. Bui, P. M. Raney, R. K. Flamm, K. Kim, R. F. Henry, D. T. W. Chu, J. J. Plattner, Y. S. Or, *J. Med. Chem.* **1998**, 41, 1651; c) T. Tanikawa, T. Asaka, M. Kashimura, K. Suzuki, H. Sugiyama, M. Sato, K. Kameo, S. Morimoto, A. Nishida, *J. Med. Chem.* **2003**, 46, 2706; d) M. C. Hsu, A. J. Junia, A. R. Haight, W. Zhang, *J. Org. Chem.* **2004**, 69, 3907.